1208 EVALUATION OF NS3 AMINO ACID VARIANTS IN A PHASE 1B STUDY OF GENOTYPE 1 (GT1) AND GT3 INFECTED PATIENTS WITH THE HCV PROTEASE INHIBITOR, MK-5172

randomization at Week 24 will determine total duration of therapy based on on-treatment response. Results: 17.4% had cirrhosis; 92.6% had a non-CC IL28B genotype. At week 12 (Table), rates of undetectable HCVRNA were 30% (DCV 20mg) and 34% (DCV 60mg) among NuR and 44% (DCV 20mg), 57% (DCV 60mg), among PaR. For the PaR placebo group (N=17), cEVR and pEVR (>2 log decline from baseline at Week 12; detectable) rates were 0% and 53%, respectively.